9618.HK
JD.US
Baozun does e-commerce tools

E-commerce giant JD.com (JD.US; 9618.HK) is in renewed talks to acquire Ceconomy AG (CEC.DE), Bloomberg reported on Wednesday, saying that JD recently approached the German electronics retailer and discussions are still ongoing.

According to the report, JD has been seeking to expand through overseas acquisitions to offset weakening growth in China as the domestic economy slows. Last year, the company considered acquiring UK electronics retailer Currys Plcbut eventually abandoned the plan.

Ceconomy currently operates around 1,000 MediaMarkt and Saturn retail stores across Europe. JD’s delivery network would complement Ceconomy’s brick-and-mortar presence, according to the Bloomberg report. JD had previously expressed interest in acquiring Ceconomy at the end of 2023.

Ceconomy’s stock has risen 30% so far this year, giving the company a market valuation of 1.65 billion euros ($1.72 billion). JD’s Hong Kong shares opened 1.2% lower at HK$155.40 on Thursday and fell 0.13% to HK$156.3 by the midday break.

By Lee Shih Ta

To subscribe to Bamboo Works weekly free newsletter, click  here

Recent Articles

Illustration of Luckin and Costa coffee being tasted

Luckin Coffee eyes global leap as China’s Double 11 loses its luster

Luckin could be preparing a bid for Costa Coffee. What's driving this potential deal, and what are its chances for success? And this year's Double 11 festival looks like a dud, with most big e-commerce companies failing to publish any big numbers. What does the future hold for this fast-fading shopping fest?
So-Young runs cosmetic surgery clinics

Can So-Young find new youth in bricks and mortar?

The cosmetic surgery specialist’s top line is growing as it opens new ‘light medical aesthetic’ clinics, but its bottom line is sagging as its older platform business evaporates Key Takeaways:…
CSPC delivered lower nine-month revenues and profits

CSPC feels the pain from sweeping cuts in drug prices

The pharmaceutical giant is paying the price for its aggressively low bids in China’s centralized drug tenders, as it shifts its focus from traditional to novel drugs Key Takeaway: The…